Cancers, Vol. 12, Pages 3271: Breast Cancer Heterogeneity and Response to Novel Therapeutics

Alexandros G.Sfakianakis shared this article with you from Inoreader Cancers, Vol. 12, Pages 3271: Breast Cancer Heterogeneity and Response to Novel Therapeutics Μέσω Cancers Cancers, Vol. 12, Pages 3271: Breast Cancer Heterogeneity and Response to Novel Therapeutics Cancers doi: 10.3390/cancers12113271 Authors: Mariona Baliu-Piqué Atanasio Pandiella Alberto Ocana Targeted cancer therapies against oncogenic drivers are actively being developed and tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation is present in most tumoral cells. Therefore, highly heterogeneous tumors may be refractory to these therapies. This makes tumor heterogeneity a major challenge in cancer therapy. Although heterogeneity has traditionally been attributed to genetic diversity within cancer cell populations, it is now widely recognized that human cancers are heterogeneous in almost all distinguishable phenotypic characteristics. Understanding the genetic variability and also the non-genetic influences of tumor heterogeneity will provide novel insights into how to reverse therapeutic resistance and improve cancer therapy. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.